

**Reference:** FOI.ICB-2324/301

**Subject:** Primary Care Rebate Scheme

*I can confirm that the ICB **does hold the information requested**; please see responses below:*

| QUESTION  | RESPONSE   |  |                   |
|---|--|--|-------------------|
| <p>I would be very grateful if you please could answer the following question:</p> <p>Which primary care rebate schemes is your ICB/ Health Board currently signed up to?</p> <p>Also if possible, please provide the start and end dates of these contracts.</p> | <b>Rebate Product</b>  | <b>Start date</b>  | <b>End date</b>   |
|   | Adcal D3   | 01/04/2018   | Until termination |
|   | BD Viva  | Company deems start dates/end dates/term as commercially sensitive |                   |
|   | Butec  | 01/04/2021   | 30/04/2024        |
|   | Buvidal  | 01/07/2021   | 31/12/2023        |
|   | Clenil   | 01/07/2022   | 30/06/2024        |
|   | Espranor   | 01/01/2022   | 31/12/2023        |
|   | Fostair NEXThaler  | 01/10/2023   | 30/09/2025        |
|   | Fostair pMDI   | 01/10/2023   | 30/09/2025        |
|   | FreeStyle Libre  | 01/09/2022   | 31/08/2024        |
|   | Gatalin XL   | 01/12/2022   | 30/11/2023        |
|   | Glucophage   | 01/07/2022   | 30/06/2024        |
|   | Onglyza  | Roll on of pre-merge agreements                                    | Until termination |
|   | Pipexus  | 01/11/2019   | Until termination |
| Prostap   | Company deems start dates/end dates/term as commercially sensitive |  |                   |

|                                  |            |                   |
|----------------------------------|------------|-------------------|
| <b>Ranexa</b>                    | 01/10/2022 | 30/09/2024        |
| <b>Stexerol</b>                  | 01/10/2018 | Until termination |
| <b>Strivit</b>                   | 01/04/2021 | 31/03/2024        |
| <b>Vizidor &amp; Vizidor Duo</b> | 01/09/2023 | 31/08/2025        |
| <b>Xaggitin</b>                  | 01/04/2018 | Until termination |
| <b>National DOAC rebate</b>      | 01/01/2022 | 31/03/2024        |

The ICB has applied Section 43(2) (Information prejudice to commercial interests) to the response. The public interest arguments in favour of disclosing the information include the ICB's responsibility to be transparent and accountable in its decision making. The ICB policy for Sponsorship of Activities by and Joint Working with the Pharmaceutical Industry outlines the values the ICB adheres to when working with the pharmaceutical industry and this includes the principle for the ICB to promote confidence between staff, patients and the public through transparency of NHS activities. The policy also outlines that information relating to rebate schemes is disclosable under the FOI Act and only information considered commercially sensitive should be redacted.

The public interest arguments in favour of maintaining the exemption includes the agreement signed by the ICB which confirms the information as commercially sensitive and the subsequent confirmation of this from the contract holder as well as their reasoning for why they consider the information commercially

|  |  |
|--|--|
|  | <p>sensitive. Rebate schemes allow organisations to offer a financial rebate to the ICB and these schemes are considered on clinical, financial and contractual grounds and will only be considered if the medicines are appropriate and of value to the ICB population. The ICB has considered that disclosure of the information may lead to the contract holder not offering this type of scheme again which may result in the ICB having to spend more public funds on prescribing. The ICB has a responsibility to secure the best use of public resources and provide value for money.</p> <p>The ICB has considered the balance of both disclosing the information and maintaining the exemption and believes that it is in the public's best interest to apply the exemption. The ability for organisations to offer rebate schemes to the ICB reduces the amount of public funding used for prescribing and allows for the more effective use of resources to ensure that the ICB achieves value for money.</p> |
|--|--|

***The information provided in this response is accurate as of 9 November 2023 and has been approved for release by Dr Joanne Medhurst, Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.***